Improving Participation of Underrepresented Populations in Clinical Trials
Awards are made from the NCORP Pilot Grant Program to foster improved representation of underserved populations in cancer clinical trial accrual. Grants from the program are issued through a competitive, peer-reviewed process, and projects are funded for up to $50,000 (direct costs) and may be spent over a 1- or 2-year award period. Indirect costs are limited to a rate of 25%. The source of these funds is nonfederal.
Fundable project proposals should:
- Establish infrastructure or test an intervention to improve access for underserved population(s);
- Strive to remove structural barriers (e.g., policies, protocol-specific);
- Be action-oriented and measurable (vs. descriptive);
- Challenge and seek to shift current research or clinical practice paradigms;
- Describe how the effort will be communicated to patients and other stakeholders;
- Be scalable for potential application at sites across the NCTN/NCORP.
Not fundable: Any proposal which solely seeks validation of an existing problem.
To be considered for a full application submission, please complete the Outline Template linked below and submit to [email protected] by June 1, 2022.
Outlines will be reviewed prior to inviting full application submissions.
In order to field questions and foster conversation, we held four opportunities for virtual drop-in office hours. If you missed these events but are interested in learning more, a recording of the final session – held during SWOG’s fall 2021 group meeting – can be be viewed here.
NCORP Pilot Grant Application FormThe Error Correction Window is 48 hours from time of submission. Should the due date fall on a weekend or holiday, the deadline is automatically extended to next business day. In case of emergency situation or extreme weather, documentation of institutional closing should be sent along with application, which must be received by 5pm local time on the first business day that the institution is open. Late submissions will not be accepted but will be referred to the next award cycle.
Made possible with generous support from:
And through a general research grant by Astellas & Pfizer, Inc.